"Glenmark Pharmaceuticals Europe today has entered into a strategic development & licensing agreement with Celon Pharma SA to develop and market a generic version of GlaxoSmithKline's Seretide Accuhaler product - Fluticasone / Salmeterol dry powder Inhaler in Europe upon commercialisation," the pharma company said in its filing.